Details of the Drug Pharmacogenomic Perturbation Atlas
General Information of Drug (ID: DMEJU1L)
| Drug Name | ||||||
|---|---|---|---|---|---|---|
| Synonyms |
IPSAPIRONE; 95847-70-4; Ipsapironum [Latin]; Ipsapirona [Spanish]; Ipsapirone [INN:BAN]; UNII-6J9B11MN0K; C19H23N5O3S; 2-[4-[4-(2-PYRIMIDINYL)-1-PIPERAZINYL]BUTYL]-1,2-BENZISOTHIAZOL-3(2H)-ONE-1,1-DIOXIDE; BRN 5486134; CHEMBL8412; 6J9B11MN0K; NCGC00025315-01; DSSTox_CID_25688; 2-(4-(4-(2-Pyrimidinyl)-1-piperazinyl)butyl)-1,2-benzisothiazol-3(2H)-one 1,1-dioxide; DSSTox_RID_81060; DSSTox_GSID_45688; Ipsapironum; Ipsapirona; 1,1-dioxo-2-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]-1,2-benzothiazol-3-one
| |||||
| Cross-matching ID | ||||||
Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
|
|
||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||
Pharmacogenomic Perturbation Across Diseases and Tissues
|
Breast
Breast adenocarcinoma
Colon
Colorectal adenocarcinoma
Kidney
Normal (Immortalized)
Lung
Lung adenocarcinoma
Non-small cell lung carcinoma
Prostate
Prostate carcinoma
Skin
Melanoma
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
